Curiel, Diamond receive innovation award

David Curiel, MD, PhD, (left) and Michael Diamond, MD, PhD, have received the Chancellor's Award for Innovation and Entrepreneurship at Washington University. The award recognizes their work to develop a nasal vaccine for COVID-19. The vaccine was licensed to Bharat Biotech and is now approved for emergency use in India. (Photo: Huy Mach/School of Medicine)

David T. Curiel, MD, PhD, and Michael S. Diamond, MD, PhD, both of Washington University School of Medicine in St. Louis, have received the Washington University Chancellor’s Award for Innovation and Entrepreneurship for their development of a nasal vaccine against SARS-CoV-2, the virus that causes COVID-19.

The vaccine, delivered via drops in the nose, was licensed to Bharat Biotech and approved for emergency use in India. In 2022, the Indian government granted emergency use authorization for the vaccine as a primary series of two doses and as a booster for people who have already received two doses of other COVID-19 vaccines.

Curiel, the Distinguished Professor of Radiation Oncology, and Diamond, the Herbert S. Gasser Professor of Medicine, created — along with members of their laboratories — the nasal vaccine in the early months of the COVID-19 pandemic. 

Read more on the School of Medicine website.

Leave a Comment

Comments and respectful dialogue are encouraged, but content will be moderated. Please, no personal attacks, obscenity or profanity, selling of commercial products, or endorsements of political candidates or positions. We reserve the right to remove any inappropriate comments. We also cannot address individual medical concerns or provide medical advice in this forum.